AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX Q4 revenue rises 6% to $954 million; 2025 EPS outlook $11.74 to $12.24

Positive Impact 3 of 5 earnings Written later

IDEXX reported fourth quarter 2024 revenue of $954 million, up 6%, and EPS of $2.62, up 13% as reported. For the full year, revenue rose 6% to $3,898 million and EPS rose 6% to $10.67, after a $0.56 per share charge tied to an ongoing litigation matter. The company also issued initial 2025 guidance of $4,055 million to $4,170 million in revenue and $11.74 to $12.24 in EPS, and assumes about $1.5 billion of share repurchases.

Key points

  • Q4 2024 revenue of $954 million, up 6% as reported and organically; Q4 EPS of $2.62, up 13% as reported
  • Full year 2024 EPS of $10.67 included a $0.56 per share negative impact from a discrete litigation expense accrual
  • 2025 outlook: revenue of $4,055 million to $4,170 million and EPS of $11.74 to $12.24, both initial estimates
  • Outlook assumes about $1.5 billion of share repurchases in 2025, subject to market conditions

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECFeb 3, 2025, 6:30 AM ET
Accession number0001104659-25-008331

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.